Hongjun Hao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Hongjun Hao has a total of 88 co-authors. Here are the top co-authors by number of shared publications:
Haiqiang Jin
Laboratory of Neuroimmunology, Department of Neurology, Peking University First Hospital, Beijing, China; Beijing Key Laboratory of Neurovascular Disease Discovery, Beijing, China
8 shared publications- Feng Gao
Department of Neurology, Peking University First Hospital
6 shared publications Zhaoxia Wang
Department of Neurology, Peking University First Hospital, Beijing, China
4 shared publicationsFeng Gao
3 shared publicationsJingjing Luo
Neurology Department, Peking University First Hospital, Beijing, China
3 shared publicationsTao Wu
Department of Neurology, Peking University First Hospital, Beijing, China
3 shared publications
Latest Publications
- 10 April 2026
- Published by Elsevier in NeuroToxicology
- Vol. 114, 103443
Brain MRI iron deposition and serum iron with multiple sclerosis: Evidence from a Mendelian randomization study
- 10 April 2026
- Published by Elsevier in NeuroToxicology
- Vol. 114, 103443
Brain MRI iron deposition and serum iron with multiple sclerosis: Evidence from a Mendelian randomization study
- 13 February 2026
- Published by Elsevier in Clinica Chimica Acta
- Vol. 586, 120906
Exploration of the source of AQP4 antibody: Based on paired serum and cerebrospinal fluid samples from 98 patients
- 13 February 2026
- Published by Elsevier in Clinica Chimica Acta
- Vol. 586, 120906
Exploration of the source of AQP4 antibody: Based on paired serum and cerebrospinal fluid samples from 98 patients
- Open Access
- 10 September 2025
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1650847
Expression of inflammatory cytokines in CADASIL and their associations with clinical and neuroimaging features
Objectives: The aim of our study is to explore the expression levels of inflammatory cytokines in patients with cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), and to assess the correlation between inflammatory cytokines and clinical/magnetic resonance imaging (MRI) features of the patients.Methods: We recruited 54 patients with CADASIL and 28 healthy controls and detected the expression levels of the following inflammatory cytokines in peripheral blood: interferon (IFN)-γ, tumor necrosis factor (TNF)-α, TNF-β, interleukin (IL)-1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-17F, and IL-22. We also analyzed the relationship between the expression levels of the inflammatory cytokines and the clinical/MRI features.Results: The expression of most inflammatory cytokines were significantly higher in CADASIL patients than in healthy controls, including IFN-γ (z = −5.335, P < 0.001), TNF-α (z = −4.880, P < 0.001), TNF-β (z = −2.401, P = 0.019), IL-1β (z = -2.831, P = 0.007), IL-4 (z = −4.039, P < 0.001), IL-5 (z = −4.523, P < 0.001), IL-6 (z = −3.545, P < 0.001), IL-8 (z = −5.667, P < 0.001), IL-17F (z = −3.986, P < 0.001) and IL-22 (z = −5.325, P < 0.001). The increased expression level of TNF-β was correlated with abnormal mRS scores in patients with CADASIL (odds ratio [OR] = 6.147, 95% CI: 1.324-28.535; P = 0.020) after adjustment for age, sex, history of hypertension and history of diabetes. The expression level of TNF-β was also associated with MMSE (β = -0.281, 95% CI:-5.325–0.866, P = 0.008) and apathy scores (β = 0.388, 95% CI:2.554-16.328, P = 0.008) after adjusting for age, sex, educational years, history of hypertension and history of diabetes. There was also a positive correlation between the expression level of TNF-β and the number of CMBs in deep (β = 0.314, 95% CI:2.989-39.461, P = 0.023) and lobar region (β = 0.433, 95% CI:15.363-59.857, P = 0.001) after adjusting for age, sex, history of hypertension and history of diabetes.Conclusions: Our results indicate that diffuse inflammatory pathway activation occurs in CADASIL. The increased expression level of TNF-β was associated with higher CMBs burden and poor clinical scores. Our findings suggest that the inflammatory pathway, particularly the TNF-related inflammatory pathway, may be involved in the disease progression of CADASIL.
- 10 September 2025
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1650847
Open AccessExpression of inflammatory cytokines in CADASIL and their associations with clinical and neuroimaging features
Objectives: The aim of our study is to explore the expression levels of inflammatory cytokines in patients with cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), and to assess the correlation between inflammatory cytokines and clinical/magnetic resonance imaging (MRI) features of the patients.Methods: We recruited 54 patients with CADASIL and 28 healthy controls and detected the expression levels of the following inflammatory cytokines in peripheral blood: interferon (IFN)-γ, tumor necrosis factor (TNF)-α, TNF-β, interleukin (IL)-1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-17F, and IL-22. We also analyzed the relationship between the expression levels of the inflammatory cytokines and the clinical/MRI features.Results: The expression of most inflammatory cytokines were significantly higher in CADASIL patients than in healthy controls, including IFN-γ (z = −5.335, P < 0.001), TNF-α (z = −4.880, P < 0.001), TNF-β (z = −2.401, P = 0.019), IL-1β (z = -2.831, P = 0.007), IL-4 (z = −4.039, P < 0.001), IL-5 (z = −4.523, P < 0.001), IL-6 (z = −3.545, P < 0.001), IL-8 (z = −5.667, P < 0.001), IL-17F (z = −3.986, P < 0.001) and IL-22 (z = −5.325, P < 0.001). The increased expression level of TNF-β was correlated with abnormal mRS scores in patients with CADASIL (odds ratio [OR] = 6.147, 95% CI: 1.324-28.535; P = 0.020) after adjustment for age, sex, history of hypertension and history of diabetes. The expression level of TNF-β was also associated with MMSE (β = -0.281, 95% CI:-5.325–0.866, P = 0.008) and apathy scores (β = 0.388, 95% CI:2.554-16.328, P = 0.008) after adjusting for age, sex, educational years, history of hypertension and history of diabetes. There was also a positive correlation between the expression level of TNF-β and the number of CMBs in deep (β = 0.314, 95% CI:2.989-39.461, P = 0.023) and lobar region (β = 0.433, 95% CI:15.363-59.857, P = 0.001) after adjusting for age, sex, history of hypertension and history of diabetes.Conclusions: Our results indicate that diffuse inflammatory pathway activation occurs in CADASIL. The increased expression level of TNF-β was associated with higher CMBs burden and poor clinical scores. Our findings suggest that the inflammatory pathway, particularly the TNF-related inflammatory pathway, may be involved in the disease progression of CADASIL.
- Open Access
- 21 August 2024
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 15, 1367252
Inflammatory cytokine expression in Fabry disease: impact of disease phenotype and alterations under enzyme replacement therapy
Objectives: The aim of this study is to explore the expression of inflammatory cytokines (ICs) in Fabry disease (FD), the correlation between ICs and FD phenotypes, and the impact of enzyme replacement therapy (ERT) on IC expression.Methods: We recruited 67 FD patients and 44 healthy controls (HCs) and detected concentrations of the following ICs: interferon-γ, interleukin (IL)-1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12P70, IL-17A, IL-17F, IL-22, tumor necrosis factor (TNF)-α, and TNF-β. We also analyzed the impact of ERT on IC expression in FD patients and the relationship between IC expression and sex, genotype, phenotype, disease burden, and biomarkers.Results: Most ICs were significantly higher in FD patients than in HCs. A number of ICs were positively correlated with clinical aspects, including disease burden (Mainz Severity Score Index [MSSI]) and cardiac and renal markers. IL-8 was higher in the high MSSI (P-adj=0.026*) than in the low MSSI.Conclusions: ICs were upregulated in FD patients, indicating the role of the innate immune process in FD etiology. ERT ameliorated FD-related inflammatory activation, at least to some extent. IC expression was positively correlated with disease burden and clinical markers in FD. Our findings indicated that the inflammatory pathway may be a promising therapeutic target for FD.
- 21 August 2024
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 15, 1367252
Open AccessInflammatory cytokine expression in Fabry disease: impact of disease phenotype and alterations under enzyme replacement therapy
Objectives: The aim of this study is to explore the expression of inflammatory cytokines (ICs) in Fabry disease (FD), the correlation between ICs and FD phenotypes, and the impact of enzyme replacement therapy (ERT) on IC expression.Methods: We recruited 67 FD patients and 44 healthy controls (HCs) and detected concentrations of the following ICs: interferon-γ, interleukin (IL)-1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12P70, IL-17A, IL-17F, IL-22, tumor necrosis factor (TNF)-α, and TNF-β. We also analyzed the impact of ERT on IC expression in FD patients and the relationship between IC expression and sex, genotype, phenotype, disease burden, and biomarkers.Results: Most ICs were significantly higher in FD patients than in HCs. A number of ICs were positively correlated with clinical aspects, including disease burden (Mainz Severity Score Index [MSSI]) and cardiac and renal markers. IL-8 was higher in the high MSSI (P-adj=0.026*) than in the low MSSI.Conclusions: ICs were upregulated in FD patients, indicating the role of the innate immune process in FD etiology. ERT ameliorated FD-related inflammatory activation, at least to some extent. IC expression was positively correlated with disease burden and clinical markers in FD. Our findings indicated that the inflammatory pathway may be a promising therapeutic target for FD.
- 23 April 2024
- Published by Springer Nature in Neurological Sciences
- Vol. 45 (7) , 2969-2976
COVID-19 in patients with myasthenia gravis: a single-center retrospective study in China
Background Coronavirus disease 2019 (COVID-19) has been a great concern since 2019. Patients with myasthenia gravis (MG) may be at higher risk of COVID-19 and a more severe disease course. We examined the associations between COVID-19 and MG. Methods This single-center retrospective cohort study involved 134 patients who were diagnosed with MG from June 2020 to November 2022 and followed up until April 2023. They were divided into a COVID-19 group and non-COVID-19 group. Logistic regression analysis was used to detect factors potentially associating COVID-19 with MG. Results Of the 134 patients with MG, 108 (80.6%) had COVID-19. A higher number of comorbidities was significantly associated with an increased risk of COVID-19 (p = 0.040). A total of 103 patients (95.4%) had mild/moderate COVID-19 symptoms, and 4 patients (3.7%) were severe/critical symptoms (including 2 deaths). Higher age (p = 0.036), use of rituximab (p = 0.037), tumors other than thymoma (p = 0.031), Hashimoto’s thyroiditis (p = 0.011), more comorbidities (p = 0.002), and a higher baseline MG activities of daily living (MG-ADL) score (p = 0.006) were risk factors for severe COVID-19 symptoms. The MG-ADL score increased by ≥ 2 points in 16 (15.7%) patients. Dry cough and/or expectoration (p = 0.011), use of oral corticosteroids (p = 0.033), and use of more than one kind of immunosuppressant (p = 0.017) were associated with the increase of the post-COVID-19 MG-ADL score. Conclusion Most patients with MG have a mild course of COVID-19. However, patients with older age, many comorbidities, a high MG-ADL score, and use of a variety of immunosuppressants during COVID-19 may be more prone to severe symptoms.
- 23 April 2024
- Published by Springer Nature in Neurological Sciences
- Vol. 45 (7) , 2969-2976
COVID-19 in patients with myasthenia gravis: a single-center retrospective study in China
Background Coronavirus disease 2019 (COVID-19) has been a great concern since 2019. Patients with myasthenia gravis (MG) may be at higher risk of COVID-19 and a more severe disease course. We examined the associations between COVID-19 and MG. Methods This single-center retrospective cohort study involved 134 patients who were diagnosed with MG from June 2020 to November 2022 and followed up until April 2023. They were divided into a COVID-19 group and non-COVID-19 group. Logistic regression analysis was used to detect factors potentially associating COVID-19 with MG. Results Of the 134 patients with MG, 108 (80.6%) had COVID-19. A higher number of comorbidities was significantly associated with an increased risk of COVID-19 (p = 0.040). A total of 103 patients (95.4%) had mild/moderate COVID-19 symptoms, and 4 patients (3.7%) were severe/critical symptoms (including 2 deaths). Higher age (p = 0.036), use of rituximab (p = 0.037), tumors other than thymoma (p = 0.031), Hashimoto’s thyroiditis (p = 0.011), more comorbidities (p = 0.002), and a higher baseline MG activities of daily living (MG-ADL) score (p = 0.006) were risk factors for severe COVID-19 symptoms. The MG-ADL score increased by ≥ 2 points in 16 (15.7%) patients. Dry cough and/or expectoration (p = 0.011), use of oral corticosteroids (p = 0.033), and use of more than one kind of immunosuppressant (p = 0.017) were associated with the increase of the post-COVID-19 MG-ADL score. Conclusion Most patients with MG have a mild course of COVID-19. However, patients with older age, many comorbidities, a high MG-ADL score, and use of a variety of immunosuppressants during COVID-19 may be more prone to severe symptoms.
- 21 April 2024
- Published by Elsevier in Clinica Chimica Acta
- Vol. 559, 119681
Significance of immunoglobulins synthesis with central nervous system involvement in Neuro-Behçet’s disease
- 21 April 2024
- Published by Elsevier in Clinica Chimica Acta
- Vol. 559, 119681
Significance of immunoglobulins synthesis with central nervous system involvement in Neuro-Behçet’s disease
- Open Access
- 1 April 2023
- Published by AME Publishing Company in Annals of Translational Medicine
- Vol. 11 (7) , 282
Application of oligoclonal bands and other cerebrospinal fluid variables in multiple sclerosis and other neuroimmunological diseases: a narrative review
Review Article Application of oligoclonal bands and other cerebrospinal fluid variables in multiple sclerosis and other neuroimmunological diseases: a narrative review Haiqiang Jin, Qianshuo Lu, Feng Gao, Hongjun Hao
- 1 April 2023
- Published by AME Publishing Company in Annals of Translational Medicine
- Vol. 11 (7) , 282
Open AccessApplication of oligoclonal bands and other cerebrospinal fluid variables in multiple sclerosis and other neuroimmunological diseases: a narrative review
Review Article Application of oligoclonal bands and other cerebrospinal fluid variables in multiple sclerosis and other neuroimmunological diseases: a narrative review Haiqiang Jin, Qianshuo Lu, Feng Gao, Hongjun Hao
- 11 March 2023
- Published by Elsevier in Clinical Immunology
- Vol. 250, 109286
Myelin basic protein and index for neuro-Behçet's disease
- 11 March 2023
- Published by Elsevier in Clinical Immunology
- Vol. 250, 109286
Myelin basic protein and index for neuro-Behçet's disease
- 22 June 2022
- Published by Elsevier in Clinica Chimica Acta
- Vol. 533, 122-130
Optimization of the cut-offs in acetylcholine receptor antibodies and diagnostic performance in myasthenia gravis patients
- 22 June 2022
- Published by Elsevier in Clinica Chimica Acta
- Vol. 533, 122-130
Optimization of the cut-offs in acetylcholine receptor antibodies and diagnostic performance in myasthenia gravis patients
- Open Access
- 12 July 2021
- Published by Springer Nature in BMC Neurology
- Vol. 21 (1) , 1-6
Myasthenia gravis associated with renal cell carcinoma: a paraneoplastic syndrome or just a coincidence
Background: Myasthenia gravis (MG) can occur as a paraneoplastic phenomenon associated with thymoma. The association of MG with renal cell carcinoma (RCC) is not clear. Herein, we describe six cases of MG associated with RCC.Methods: There were 283 patients diagnosed with MG admitted to our hospital from 2014 to 2019. Among them, 6 patients also had RCC. None of them had immune checkpoint inhibitor therapies. We performed a retrospective clinical data collection and follow-up studies of these 6 patients.Results: These 6 patients with an average MG onset age of 61.3 ± 13.3 years, were all positive for anti-acetylcholine receptor antibodies. MG symptoms appeared after RCC resection in 3 cases. RCC was discovered after the onset of MG in 2 cases, and synchronously with MG in 1 case. After nephrectomy, the MG symptoms showed a stable complete remission in 1 case. Among them, four patients met the diagnostic criteria of possible paraneoplastic neurological syndromes.Conclusions: Except for thymoma, patients with MG should pay attention to other tumors including RCC. MG may be a paraneoplastic syndrome of RCC, and further studies are needed to elucidate the relationship.
- 12 July 2021
- Published by Springer Nature in BMC Neurology
- Vol. 21 (1) , 1-6
Open AccessMyasthenia gravis associated with renal cell carcinoma: a paraneoplastic syndrome or just a coincidence
Background: Myasthenia gravis (MG) can occur as a paraneoplastic phenomenon associated with thymoma. The association of MG with renal cell carcinoma (RCC) is not clear. Herein, we describe six cases of MG associated with RCC.Methods: There were 283 patients diagnosed with MG admitted to our hospital from 2014 to 2019. Among them, 6 patients also had RCC. None of them had immune checkpoint inhibitor therapies. We performed a retrospective clinical data collection and follow-up studies of these 6 patients.Results: These 6 patients with an average MG onset age of 61.3 ± 13.3 years, were all positive for anti-acetylcholine receptor antibodies. MG symptoms appeared after RCC resection in 3 cases. RCC was discovered after the onset of MG in 2 cases, and synchronously with MG in 1 case. After nephrectomy, the MG symptoms showed a stable complete remission in 1 case. Among them, four patients met the diagnostic criteria of possible paraneoplastic neurological syndromes.Conclusions: Except for thymoma, patients with MG should pay attention to other tumors including RCC. MG may be a paraneoplastic syndrome of RCC, and further studies are needed to elucidate the relationship.